Thrombotic disorders—such as ischemic stroke, heart attack, pulmonary embolism, and deep vein thrombosis—are principal contributors to global mortality. However, conventional thrombolytic therapies are often constrained by poor targeting and limited control over the local coagulation environment. In short, they may increase the risk of systemic bleeding and fail to reduce the chance of future clotting at the thrombotic site—thus reducing efficacy and increasing adverse events.